# Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene

> **NCT01243346** · PHASE2 · COMPLETED · sponsor: **Arog Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- D842-related Mutant GIST

## Interventions

- **DRUG:** Crenolanib besylate (CP-868,596-26), Dose: 140mg BID

## Key facts

- **NCT ID:** NCT01243346
- **Lead sponsor:** Arog Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-06-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243346, "Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01243346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*